Video Monitoring and Payments to Help People Finish Latent Tuberculosis Treatment
Tests video-observed dosing with payments to help adults with latent tuberculosis finish treatment.
Plain-language title generated from the registry record
Registry title: Economic Incentives and vDOT for Latent Tuberculosis Infection
Key facts
- Where
- Baltimore, United StatesSee the site
Where in United States
- Baltimore City Health Department, and Baltimore metropolitan area clinics and health departmentsBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT05022862
- Record updated
- 4 May 2026
- Original description
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.Read full original descriptionShow less
Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
Inclusion: 18 years old or older,; diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians; reside in Baltimore metro area; speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board; prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin.
Exclusion: younger than 18 years old; pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated); diagnosed with active TB; prescribed an alternative treatment regimen for latent TB; participant's spoken language does not have a translated long or short consent form.